Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma

British Journal of Cancer

Volumn 90, Issue 2, 2004, Pages 503-509

  Soufir, N ^a   Lacapere, J J ^a   Bertrand, G ^a   Matichard, E ^a   Meziani, R ^a   Mirebeau, D ^b   Descamps, V ^a   Gerard B ^a   Archimbaud, A ^c   Ollivaud, L ^c   Bouscarat, F ^a   Baccard, M ^c   Lanternier, G ^d   Saiag P ^e   Lebbe C ^c   Basset Seguin, N ^c   Crickx, B ^a   Cave, H ^b   Grandchamp, B ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d PERCY MILITARY HOSPITAL   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Cdk4; Deletion; Germline mutation; INK4 ARF; Melanoma genetics

Indexed keywords

CYCLIN DEPENDENT KINASE 4;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOANALYSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FAMILIAL CANCER; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC RISK; GERM LINE; HIGH RISK PATIENT; HUMAN; INK4A ARF GENE; MAJOR CLINICAL STUDY; MELANOMA; MULTIPLE CANCER; MUTATIONAL ANALYSIS; ONSET AGE; PANCREAS CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN VARIANT; QUANTITATIVE ANALYSIS; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; PEDIGREE; POLYMERASE CHAIN REACTION; RISK FACTORS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 10744230299     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601503     Document Type: Article

References (62)

1. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N (1999) CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91: 446-452
2. Alao JP, Mohammed MQ, Retsas S (2002) The CDKN2A tumour suppressor gene: no mutations detected in patients with melanoma and additional unrelated cancers. Melanoma Res 12: 559-563
3. Ashcroft M, Vousden KH (1999) Regulation of p53 stability. Oncogene 18: 7637-7643
4. Auroy S, Avril MF, Chompret A, Pham D, Goldstein AM, Bianchi-Scarra G, Frebourg T, Joly P, Spatz A, Rubino C, Demenais F, Bressac-de Paillerets B (2001) Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 32: 195-202
5. Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M (1998) Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 58: 2298-2303
6. Bastiaens M, ter Huurne J, Gruis N, Bergman W, Westendorp R, Vermeer BJ, Bavinck JN (2001) The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet 10: 1701-1708
7. Becker TM, Rizos H, Kefford RF, Mann GJ (2001) Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent Kinase 4 binding. Clin Cancer Res 7: 3282-3288
8. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H (2003) CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono-and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 37: 44-57
9. Bertram CG, Gaut RM, Barrett JH, Pinney E, Whitaker L, Turner F, Bataille V, Dos Santos Silva I, A JS, Bishop DT, Newton Bishop JA (2002) An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 119: 961-965
10. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92: 1260-1266
11. Dilworth D, Liu L, Stewart AK, Berenson JR, Lassam N, Hogg D (2000) Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood 95: 1869-1871
12. Flores JF, Pollock PM, Walker GJ, Glendening JM, Lin AH, Palmer JM, Walters MK, Hayward NK, Fountain JW (1997) Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 15: 2999-3005
13. Ginzinger DG (2002) Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 30: 503-512
14. Goldstein AM, Chidambaram A, Halpern A, Holly EA, Guerry ID, Sagebiel R, Elder DE, Tucker MA (2002) Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res 12: 51-55
15. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark Jr WH, Tucker MA (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations [see comments]. N Engl J Med 333: 970-974
16. Greene MH (1999) The genetics of hereditary melanoma and nevi. 1998 update. Cancer 86: 2464-2477
17. Guldberg P, Kirkin AF, Gronbaek K, thor Straten P, Ahrenkiel V, Zeuthen J (1997) Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 72: 780-783
18. Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BA, Mann GJ, Bishop DT, Newton Bishop J (2000) Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 28: 45-57
19. Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Bishop JN (1997) Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6: 2061-2067
20. Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J (2000) CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 60: 6864-6867
21. Hayward N (2000) New developments in melanoma genetics. Curr Oncol Rep 2: 300-306
22. Holland EA, Schmid H, Kefford RF, Mann GJ (1999) CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 25: 339-348
23. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark Jr WH, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nat Genet 8: 15-21
24. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Mild Y, Weaver-Feldhaus J et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8: 23-26
25. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659
26. Kanetsky PA, Holmes R, Walker A, Najarian D, Swoyer J, Guerry D, Halpern A, Rebbeck TR (2001) Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 10: 509-513
27. Kato T, Suetake T, Sugiyama Y, Tabata N, Tagami H (1996) Epidemiology and prognosis of subungual melanoma in 34 Japanese patients. Br J Dermatol 134: 383-387
28. Kefford R, Bishop JN, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, Goldstein A, Puig S, Mackie R, Elder D, Hansson J, Hayward N, Hogg D, Olsson H (2002) Genetic testing for melanoma. Lancet Oncol 3: 653-654
29. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA (1999) Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the melanoma genetics consortium. J Clin Oncol 17: 3245-3251
30. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bouwes Bavinck JN (2001) Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 117: 294-300
31. Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA, Hemminki K (2001) A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 95: 388-393
32. Lal G, Liu L, Hogg D, Lassam NJ, Redston MS, Gallinger S (2000) Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer 27: 358-361
33. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D (1999) Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21: 128-132
34. MacKie RM, Andrew N, Lanyon WG, Connor JM (1998) CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 111: 269-272
35. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215
36. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ (1998) CDKN2A mutations in multiple primary melanomas. N Engl J Med 338: 879-887
37. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA (2000) Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 66: 176-186
38. Piepkorn M (2000) Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 42: 705-722 quiz 723-726
39. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723
40. Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Lai JL, Bauters F, Wattel E, Fenaux P (1995) p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 85: 657-663
41. Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN, Bishop DT (2001) A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10: 55-62
42. Rizos H, Darmanian AP, Holland EA, Mann GJ, Kefford RF (2001a) Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 276: 41424-41434
43. Rizos H, Darmanian AP, Mann GJ, Kefford RF (2000) Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene 19: 2978-2985
44. Rizos H, Puig S, Badenas C, Malvehy J, Darmanian AP, Jimenez L, Mila M, Kefford RF (2001b) A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20: 5543-5547
45. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP (1998) Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395: 237-243
46. Saida T (2001) Recent advances in melanoma research. J Dermatol Sci 26: 1-13
47. Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695
48. Simon M, Koster G, Menon AG, Schramm J (1999) Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas. Acta Neuropathol (Berl) 98: 444-452
49. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B (1998a) Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7: 209-216
50. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B (1998b) Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941]. Hum Mol Genet 7: 209-216
51. Soufir N, Daya-Grosjean L, de La Salmoniere P, Moles JP, Dubertret L, Sarasin A, Basset-Seguin N (2000) Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients. J Natl Cancer Inst 92: 1841-1847
52. Strange RC, Ellison T, Ichii-Jones F, Bath J, Hoban P, Lear JT, Smith AG, Hutchinson PE, Osborne J, Bowers B, Jones PW, Fryer AA (1999) Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 9: 269-276
53. Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG (2000) Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 136: 1118-1122
54. Ueki K, Rubio MP, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN (1994) MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 3: 1841-1845
55. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ (1995) Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 11: 328-330
56. Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW (1995) Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 4: 1845-1852
57. Whiteman DC, Milligan A, Welch J, Green AC, Hayward NK (1997) Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst 89: 1460
58. Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, Wojnarowska F, Welsh KI (2000) A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 60: 5612-5616
59. Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F, Jablons DM (2000) Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 92: 636-641
60. Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET (1996) Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst 88: 1489-1491
61. Zhuang SM, Schippert A, Haugen-Strano A, Wiseman RW, Soderkvist P (1998) Inactivations of p16INK4a-alpha, p16INK4a-beta and p15INK4b genes in 2′,3′-dideoxycytidine-and 1,3-butadiene-induced murine lymphomas. Oncogene 16: 803-808
62. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12: 97-99